

## Resilience Amidst Industry Turbulence: CRO Making a Difference

21 November 2025 | Views | By Dr Manisha Ginde, Co-Founder, President & Managing Director, DiagnoSearch Life Sciences

**Next phase of clinical research will be shaped by AI, automation, and data-driven decision-making**



India's clinical research landscape has undergone a remarkable evolution. From modest beginnings in the early 1990s to becoming a globally recognised destination for trials, the sector has matured significantly in terms of science, ethics, and regulatory oversight. Regulations have become more robust, with stronger emphasis on patient safety and quality assurance.

Globally, the clinical research market was valued at \$80.74 billion in 2023 and is projected to reach \$123.54 billion by 2030. Closer home, the Indian CRO market is set to nearly double from \$0.73 billion in 2024 to \$1.32 billion by 2032, reflecting India's growing role in the global healthcare ecosystem. This growth underscores the crucial role CROs play in helping sponsors bring life-saving therapies to patients responsibly and efficiently.

Resilience, in the context of CROs, goes beyond merely weathering change -it is about adapting, innovating, and emerging stronger from every challenge. Over the years, CROs have had to navigate shifting regulatory landscapes, mergers, acquisitions, and technological disruptions.

True resilience comes from balancing scientific excellence with regulatory compliance and operational agility. For instance, during the pandemic, many CROs, including DiagnoSearch re-engineered their processes by adopting decentralised models, digital data capture, and e-consent systems to ensure continuity of care. Such agility safeguarded ongoing studies and also reinforced trust among sponsors and patients alike.

The next phase of clinical research will be shaped by AI, automation, and data-driven decision-making. However, innovation

must always align with ethical and regulatory frameworks. The key lies in selective adoption - embracing technology that enhances efficiency, transparency, and data integrity without compromising compliance.

India's evolution in clinical research highlights the importance of foresight, credibility, and collaboration. CROs that have thrived are those that invested early in people, training, and infrastructure laying a foundation built on trust and quality. Building long-term partnerships with sponsors, regulators, and investigators has been instrumental in aligning Indian research standards with global expectations.

Each challenge be it regulatory transitions, global competition, or the pandemic has offered valuable lessons in refining processes and reinforcing ethical standards. Ultimately, the industry's progress reflects a shared commitment to science and patient welfare.

In conclusion, the clinical research industry's future belongs to organizations that can evolve responsibly where resilience is defined by adaptability, credibility, and an unyielding focus on patient welfare.

Dr Manisha Ginde, Co-Founder, President & Managing Director, DiagnoSearch Life Sciences

*DiagnoSearch, co-founded on 29th November, 1995 by D. Vasudeo Ginde and Dr Manisha Ginde, began as India's first Central Laboratory dedicated exclusively to clinical research. Over the last 30 years, it has evolved into a Full-Service Clinical Research Organisation (CRO), driven by continuous innovation, scientific expertise, and strong leadership.*